Investorideas.com newswire, breaking news for marijuana, cannabis and hemp stocks

Monday, 4 November 2019

#CBD Sector Continues to Mature – Sector Snapshot on CBD Brands and Opportunities (OTC: $RLBD) and (NYSE: $ACB), (NYSE: $APHA), (OTC: $TGIFF)


#CBD Sector Continues to Mature – Sector Snapshot on CBD Brands and Opportunities (OTC: $RLBD) and (NYSE: $ACB), (NYSE: $APHA), (OTC: $TGIFF)

Point Roberts WA, Delta BC – November 4, 2019 - Investorideas.com, a leading investor news resource covering cannabis and hemp stocks releases a sector snapshot reporting on the growth of the CBD industry and how companies are looking to differentiate their unique brands.


According to a report ‘Trends in Internet Searches for Cannabidiol (CBD) in the United States’, Google searches for CBD are seeing exponential growth as popularity and availability increases. ”Searches for CBD are now rivaling searches for yoga and electronic cigarettes, with 0.96 and 0.85 of their respective search volumes, and are searched for more than half as much as dieting.”

Another recent report stated, “As applications for cannabidiol are brought to market across diverse industries such as cosmetics, health products, food and beverage, pet products, skin care, and pharmaceuticals, the collective market for CBD sales is expected to exceed $20 billion in the United States by 2024,” according to BDS Analytics and Arcview Market Research.

“We’re witnessing CBD maturing from a cannabis sub-category into a full-blown industry of its own,” said Roy Bingham, Co-Founder and CEO of BDS Analytics. “Our growth forecast for the CBD market, across all distribution channels, predicts a compound annual growth rate of 49 percent by 2024. This is a great opportunity for all involved, but it means the road ahead will include decisions that need to be informed by the best possible data.”

As major retailers continue to announce their stocking and private label development of CBD products, BDS Analytics predicts that the majority of CBD product sales will soon occur in general retail stores, rather than cannabis dispensaries, as is currently the case. Moving forward, BDS Analytics market insights indicate that the success of products is dependent on education and understanding, dosing and consistent labeling.

BDS Analytics feels CBD is in a unique position compared to other nutraceutical or supplement ingredients for two reasons: 1) as an active ingredient in cannabis, it has a storied history of health and wellness use and anecdotal evidence of efficacy, and 2) it is one of the few natural remedies with scientific basis for at least some of the claims being made about its curative powers. Unsurprisingly, consumers are fascinated by the perceived benefits of CBD.

This growth and drive of the CBD industry is bringing in major branding opportunities such as sports and celebrity endorsements for each innovative formula.

Real Brands, Inc. (OTC: RLBD), a leading brand building company in the legal Hemp-Derived CBD consumer products category, announced that it has closed the previously announced acquisition of the proprietary CBD formulas from Integrative Medicine US of Coral Springs, Florida. The formulas consist of Ancient Chinese and other Ancient Herbal Remedies that are paired with the latest scientific breakthroughs in endocannabinoid systems, nutrients and hemp-derived CBD.

“We are pleased to announce the signing of the definitive agreement to acquire these proprietary formulas," said Real Brands, Inc. CEO, Jerry Pearring. “Since completing our audit earlier this month, we are now focusing on launching our brands and E-commerce website,” added Pearring. “We are concluding the final steps in developing our unique packaging design and formulations for each of our brands: CBD Pharmacy™, HempAid®, Humboldt Brands® and Omegahemp™. This acquisition bolsters our efforts to offer consumers innovative CBD products and, as we previously announced, we intend to use these formulas for our CBD Pharmacy™ brand and feature the Chinese symbol for healing in our new logo.”

In addition, as part of this acquisition, Jonathan Fields, AP DOM, has entered into an agreement to formulate additional products for Real Brands and become the initial member of Real Brands, Inc.’s Advisory Board. “I’m pleased to become a member of the Real Brands team and look forward to applying my education and ongoing research into traditional eastern medical therapies to create delivery mechanisms that act synergistically with CBD,” said Fields.

Aphria Inc. (TSX: APHA) (NYSE: APHA) recently reported its results for the first quarter ended August 31, 2019, with a net revenue of $126.1 million in the first quarter, an increase of 849% from prior year quarter and a decrease of 2% from the prior quarter, revenue for adult-use cannabis of $20.0 million in the first quarter, an increase of 8% from the prior quarter and a net income of $16.4 million and adjusted EBITDA of $1.0 million in the first quarter.

"We are pleased to report a second consecutive quarter of profitable growth with strong contribution from our Canadian cannabis operations. Our success was also driven by our international business and the strength and growth of our brands, particularly Broken Coast, despite a small fire at our British Columbia facility at the end of the quarter. This solid start to the year keeps us on track to achieve our fiscal year 2020 financial outlook," stated Irwin D. Simon, CEO of Aphria, Inc. "Going forward, we remain focused on our highest-return priorities both in Canada and internationally as our team furthers the development of our medical and adult-use cannabis brands to drive growth through innovation and return value to shareholders."

The company, through its subsidiary Aphria Deutschland GmbH launched their CBD-based nutraceutical, featuring CBD derived from hemp, CannRelief. The brand of products are being produced in the European Union and distributed by the Company's subsidiary, CC Pharma, which has access to more than 13,000 pharmacies throughout Germany.

"We are excited to introduce our first brand of CBD products for the German nutraceutical and cosmetics market," said Jakob Ripshtein, President of Aphria. "Supported by our extensive distribution network through CC Pharma, CannRelief provides a natural extension to Aphria's growing business opportunities in the German medical cannabis market. We look forward to providing a full range of CannRelief CBD products this year."

CannRelief CBD oils are being sold in both a 5% and 10% CBD concentration and can be found in select stores across Germany. A range of skincare and other products, including creams, serums and masks will be introduced under the CannRelief brand in a phased rollout in 2019.

Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB), a Canadian company that's defining the future of cannabis worldwide, and the UFC, the world's premier mixed martial arts organization, announced their launch of a joint clinical research program that will produce multiple studies under the terms of their recently announced partnership.

The ground-breaking research partnership is aimed at understanding key health and recovery needs of elite athletes in such a highly physical and competitive sport as mixed martial arts. Research data will then be used to drive the development of science-backed, hemp-derived CBD topicals that will be safe and reliable. These new products will help combat the rapidly growing market of untested CBD treatments currently being used by high-performance and non-professional athletes.    

Once research is complete, any resulting product will come to life in the US under the new high-performance sports brand ROAR Sports, a portfolio of high-quality, hemp-derived CBD topical treatments scientifically formulated with elite athletes in mind. Through analysis of athlete needs and scientific data, ROAR Sports will challenge the status quo, seek to alleviate the stresses of competition, and earn designation as the "Official CBD product of UFC."

The multi-phase clinical study at the UFC Performance Institute® in Las Vegas will be led by Dr. Jason Dyck, Chair of Aurora's Global Scientific Oversight Committee; Dr. Kelly Narine, Aurora's Vice President Global Research and Medical Affairs; and the team of sports performance experts at the UFC Performance Institute, led by Dr. Duncan French, UFC Vice President of Performance. Using active UFC athletes on a strictly voluntary basis, the study will help establish peer-reviewed, publishable research in this area. Products will be developed in full compliance with U.S. federal law and with UFC's anti-doping program, which adheres to WADA and USADA regulations.

"Our partnership with UFC is about committing to the science that will educate and advocate," said Aurora CEO, Terry Booth. "We are going to work together to change the way people think, to change the industry, and to launch the first hemp-derived CBD products that are backed by scientific research. The brand-building and product development are all part of our move into the U.S., and in collaboration with UFC, and we intend to play a major role in that market."

"We know anecdotally that professional athletes across sports disciplines are turning to hemp-derived CBD treatments to assist with physical recovery, with varying degrees of success," added Jason Dyck, Chair of Aurora's Global Scientific Oversight Committee. "The work we do in partnership with UFC will create an evidence-based, science-backed pipeline of consistent, and 'clean' hemp-derived CBD topicals that the high-performance athletes of UFC can rely on to treat the pain, inflammation, injury and other conditions associated with competing at such a high level."

"Collaborating with Aurora is the best way to educate ourselves and our fighters about the impact of CBD on MMA athletes and our sport," said Dr. Duncan French, UFC's Vice President of Performance. "We want to apply science and see where it leads us.  Ideally, these studies will give us the clarity we need to determine the effectiveness of hemp-derived CBD on athlete health and injury recovery." 

"Although CBD is allowed under USADA and WADA regulations, we want to be the leaders on educating UFC athletes on CBD use," said Jeff Novitzky, UFC Senior Vice President of Athlete Health & Performance. "Athlete safety is a top priority for UFC, and we will collaborate with Aurora to ensure that any new products are third-party tested for all WADA-prohibited substances to make certain they meet WADA standards."

1933 Industries Inc. (CSE: TGIF) (OTC: TGIFF), a vertically integrated cannabis consumer packaged goods company, recently announced that it will introduce its newest product, the Birdhouse CBD Balm by Canna Hemp X™, on November 4th, 2019. The CBD Balm was developed in collaboration with Birdhouse Skateboards™, targeting the action sports market and will be available for sale in dispensaries, wellness stores, skate shops and specialty retailers, including Zumiez in the United States.

Focusing on the wellness market through the creation of innovative products that enhance and improve people's lives, the Company's CBD-infused line is nationally recognized for its quality and purity of ingredients. Building on its already successful Canna Hemp X™ brand, the new Birdhouse CBD Balm is a must-have for any athlete in need of fast results before, during, and after exercise. The quick-acting Birdhouse CBD Balm is specially formulated with a blend of essential oils, arnica, peppermint, menthol and other natural ingredients. With broad-spectrum CBD, all Canna Hemp™ products are nanoparticulated to ensure total transdermal absorption for maximum effects, while being 100% THC-free.

The sports world is fast embracing the use of cannabidiol or CBD, one of over 100 non-psychoactive and non-addictive compounds extracted from the cannabis plant, in a variety of new products aimed at enhancing performance and recovery. Pro and amateur athletes are now advocating CBD as an alternative to opioid use. "We are just starting to scratch the surface of the many applications associated with the cannabis plant and we are pleased to be part of a national conversation about its potential. The anecdotal benefits keep mounting and we believe that this market is underserved," commented Mr. Chris Rebentisch, 1933 Industries CEO.

He added, "We constantly improve our formulations through research and we worked closely with the Birdhouse team over several months to develop a next-generation CBD topical product that would have wide appeal in the sports world. We are pleased to unveil the Birdhouse CBD Balm that both companies are proud to endorse."

Internationally recognized skateboarding legend Mr. Tony Hawk, Founder of Birdhouse Skateboards™ said, "The Birdhouse CBD Balm is our first collaboration with the team at Canna Hemp X™ and was created with skateboarders and athletes of all levels in mind. Sports like skateboarding require the highest quality recovery products to sustain longevity. We also hope to create awareness of the potential of CBD and in making natural products more accessible nationwide."

As this CBD industry continues to grow, in many ways almost independent of the cannabis sector, brand awareness will become essential as consumers gain more familiarity and awareness of the Hemp/CBD space. As one recent news piece put it, “CBD now has ‘a life of its own’”, and it will be the companies able to build their brands out early through sponsorship agreements, as well as show consistent quality of their innovative formulas that will stand ahead of the rest.

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining,  the AI Eye .

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses of all investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: this news article featuring Real Brands, Inc. RLBD is a paid for news release on Investorideas.com – third party (two thousand) More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Follow us on Social Media

Contact Investorideas.com
800-665-0411

Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories



Friday, 1 November 2019

Investorideas.com - Cannabis Stock News: SOL Global (CSE: SOL) (OTCPK: SOLCF) Announces Intention to Commence Normal Course Issuer Bid to Repurchase up to 5% of its Common Shares

Investorideas.com - Cannabis Stock News: SOL Global (CSE: SOL) (OTCPK: SOLCF) Announces Intention to Commence Normal Course Issuer Bid to Repurchase up to 5% of its Common Shares

Get the latest Cannabis and Hemp stock news from www.investorideas.com

Investor Ideas adds New #Stocks in Cannabis (CSE: $MXT.C) (CSE: $PRMO.C), Biotech (Nasdaq: $IPHA, $VIR, $BNRX, $FREQ) and Tech (CSE: $AMPD.C) (CSE: $TKR.C)

Investor Ideas adds New #Stocks in Cannabis (CSE: $MXT.C) (CSE: $PRMO.C), Biotech (Nasdaq: $IPHA, $VIR, $BNRX, $FREQ) and Tech (CSE: $AMPD.C) (CSE: $TKR.C)




Point Roberts WA, Delta BC, November 1, 2019 – (Investorideas.com Newswire) Investorideas.com, a global news source and leading investor resource announces its weekly roundup of stocks added to its global stock directories in cannabis, biotech and tech.


This week’s new cannabis companies are both CSE-listed and are involved in COextraction and financing for the cannabis industry, respectively.

The latest biotech/life sciences companies are all October Nasdaq IPOs.

The newest tech companies are both CSE-listed and are involved in cloud computing and IoT & AI, respectively.

New Cannabis Companies:
MedXtractor Corp. (CSE:MXT) is a Calgary-based company that manufactures patented, proprietary small-scale carbon dioxide-based extractors that are used to extract essential oils and compounds from a variety of botanical materials. At present, the Corporation targets the "Craft" cannabis grower. Craft growers are those whose crop is up to 800 indoor-sized plants per crop cycle. In management's opinion, CO2 Extractors represent the state-of-the-art for high-potency, high-purity oils, one of the fastest growing segments of the overall cannabis market. Cannabis oils can be extracted from flowers (bud), trim (leaves) and/or post-pressed rosin "chips" (leftovers from hydraulic press extraction). The ongoing worldwide legalization of cannabis is underpinning the rapidly growing demand for cannabis products with major growth seen in oils due to their utility as feedstock for various ingestion methods. The Corporation owns the patents on its CO2 Extractors.

Primo Nutraceuticals Inc. (CSE:PRMO) formerly Bougainville Ventures Inc - provides strategic capital to the thriving cannabis cultivation sector through ownership and development of commercial real estate properties. We offer fully built out turnkey facilities equipped with state-of-the-art growing infrastructure to cannabis growers and processors. Cultivators lease these facilities and pay affordable fee-based management costs to accelerate market entry and scalability. The first 10,000 square feet of greenhouse space in Oroville, Washington has been completed and is ready for occupancy. Our facilities remove financial barriers for cannabis cultivators as traditional funding is limited due to United States federal laws and current lending practices.

New Biotech Companies:
INNATE PHARMA SA (NasdaqGS: IPHA) is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia (HCL). Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need. Innate Pharma has been a pioneer in the understanding of NK cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

VIR BIOTECHNOLOGY, INC(NasdaqGS:VIR) is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of five product candidates targeting hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis

BIONTECH SE (NasdaqGS:BNTX) was founded in 2008 on the understanding that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized. Its cutting-edge pipeline includes individualized mRNA-based product candidates, innovative chimeric antigen receptor T cells, novel checkpoint immunomodulators, targeted cancer antibodies and small molecules. BioNTech has established relationships with seven pharmaceutical collaborators, including Eli Lilly and Company, Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant and Pfizer, and has published over 150 peer-reviewed publications on its scientific approach.

FREQUENCY THERAPEUTICS, INC(NasdaqGS:FREQ) is a leader in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases. The company’s progenitor cell activation (PCA) approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies. The company’s lead product candidate, FX-322, is designed to regenerate auditory hair cells to restore hearing function. In a FX-322 Phase 1/2 study, the company observed statistically significant and clinically meaningful improvement in key measures of hearing function in patients with sensorineural hearing loss. The company is evaluating additional diseases where its PCA approach could create functional tissue, including a development program in multiple sclerosis. Headquartered in Woburn, Mass., Frequency has a development and commercialization agreement with Astellas Pharma Inc. for FX-322, for which it retains U.S. rights, as well as additional collaboration agreements with academic and nonprofit research organizations including The Scripps Research Institute, Massachusetts Eye and Ear, and the Massachusetts Institute of Technology.

VIELA BIO, INC. (NasdaqGS:VIE) headquartered in Gaithersburg, Maryland, is a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases.

APREA THERAPEUTICS, INC. (NasdaqGS:APRE) is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate  mutant tumor suppressor protein, p53. The Company’s lead product candidate is APR-246, a small molecule in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

Neovasc, Inc. (TSX: NVCN.TONASDAQ: NVCN) is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and Tiara, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. 

New Tech Companies:
AMPD Ventures Inc. (CSE:AMPD) specializes in providing high-performance cloud and compute solutions for low-latency applications including video games and eSports, digital animation and visual effects, and big data collection, analysis and visualization.

Tracker Ventures Corp. (CSE:TKR) – formerly TrackLoop - is an analytics software company that is leveraging digital asset technology to transform and modernize multiple industries. TrackLoop is taking a diversified approach to the analytics and technology space, delivering practical solutions in the finance, logistics, cannabis, and pharmaceutical industries. The Company’s turnkey real-time tracking solutions offer the very latest in IoT and AI, providing valuable data and business intelligence to some of the world’s leading brands.

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Learn more about our news, PR and social media services at Investorideas.com

Follow us on Twitter https://twitter.com/Investorideas
Download our Mobile App for iPhone and Android  

To sponsor a daily podcast for the month or to be an expert guest please contact us!

Contact Investorideas.com
800-665-0411
























The Search for #CBD Products – How Real Brands (OTC: $RLBD) and (NYSE: $ACB), (NYSE: $APHA), (OTC: $TGIFF) Meet Growing Demand


The Search for #CBD Products – How Real Brands (OTC: $RLBD) and (NYSE: $ACB), (NYSE: $APHA), (OTC: $TGIFF)  Meet Growing Demand

Point Roberts WA, Delta BC – November1, 2019 - Investorideas.com, a leading investor news resource covering cannabis and hemp stocks releases a sector snapshot reporting on the growth of the CBD industry and how companies are looking to differentiate their unique brands.


According to a report ‘Trends in Internet Searches for Cannabidiol (CBD) in the United States’, Google searches for CBD are seeing exponential growth as popularity and availability increases. ”Searches for CBD are now rivaling searches for yoga and electronic cigarettes, with 0.96 and 0.85 of their respective search volumes, and are searched for more than half as much as dieting.”

Another recent report stated, “As applications for cannabidiol are brought to market across diverse industries such as cosmetics, health products, food and beverage, pet products, skin care, and pharmaceuticals, the collective market for CBD sales is expected to exceed $20 billion in the United States by 2024,” according to BDS Analytics and Arcview Market Research.

“We’re witnessing CBD maturing from a cannabis sub-category into a full-blown industry of its own,” said Roy Bingham, Co-Founder and CEO of BDS Analytics. “Our growth forecast for the CBD market, across all distribution channels, predicts a compound annual growth rate of 49 percent by 2024. This is a great opportunity for all involved, but it means the road ahead will include decisions that need to be informed by the best possible data.”

As major retailers continue to announce their stocking and private label development of CBD products, BDS Analytics predicts that the majority of CBD product sales will soon occur in general retail stores, rather than cannabis dispensaries, as is currently the case. Moving forward, BDS Analytics market insights indicate that the success of products is dependent on education and understanding, dosing and consistent labeling.

BDS Analytics feels CBD is in a unique position compared to other nutraceutical or supplement ingredients for two reasons: 1) as an active ingredient in cannabis, it has a storied history of health and wellness use and anecdotal evidence of efficacy, and 2) it is one of the few natural remedies with scientific basis for at least some of the claims being made about its curative powers. Unsurprisingly, consumers are fascinated by the perceived benefits of CBD.

This growth and drive of the CBD industry is bringing in major branding opportunities such as sports and celebrity endorsements for each innovative formula.

Real Brands, Inc. (OTC: RLBD), a leading brand building company in the legal Hemp-Derived CBD consumer products category, announced that it has closed the previously announced acquisition of the proprietary CBD formulas from Integrative Medicine US of Coral Springs, Florida. The formulas consist of Ancient Chinese and other Ancient Herbal Remedies that are paired with the latest scientific breakthroughs in endocannabinoid systems, nutrients and hemp-derived CBD.

“We are pleased to announce the signing of the definitive agreement to acquire these proprietary formulas," said Real Brands, Inc. CEO, Jerry Pearring. “Since completing our audit earlier this month, we are now focusing on launching our brands and E-commerce website,” added Pearring. “We are concluding the final steps in developing our unique packaging design and formulations for each of our brands: CBD Pharmacy™, HempAid®, Humboldt Brands® and Omegahemp™. This acquisition bolsters our efforts to offer consumers innovative CBD products and, as we previously announced, we intend to use these formulas for our CBD Pharmacy™ brand and feature the Chinese symbol for healing in our new logo.”

In addition, as part of this acquisition, Jonathan Fields, AP DOM, has entered into an agreement to formulate additional products for Real Brands and become the initial member of Real Brands, Inc.’s Advisory Board. “I’m pleased to become a member of the Real Brands team and look forward to applying my education and ongoing research into traditional eastern medical therapies to create delivery mechanisms that act synergistically with CBD,” said Fields.

Aphria Inc. (TSX: APHA) (NYSE: APHA) recently reported its results for the first quarter ended August 31, 2019, with a net revenue of $126.1 million in the first quarter, an increase of 849% from prior year quarter and a decrease of 2% from the prior quarter, revenue for adult-use cannabis of $20.0 million in the first quarter, an increase of 8% from the prior quarter and a net income of $16.4 million and adjusted EBITDA of $1.0 million in the first quarter.

"We are pleased to report a second consecutive quarter of profitable growth with strong contribution from our Canadian cannabis operations. Our success was also driven by our international business and the strength and growth of our brands, particularly Broken Coast, despite a small fire at our British Columbia facility at the end of the quarter. This solid start to the year keeps us on track to achieve our fiscal year 2020 financial outlook," stated Irwin D. Simon, CEO of Aphria, Inc. "Going forward, we remain focused on our highest-return priorities both in Canada and internationally as our team furthers the development of our medical and adult-use cannabis brands to drive growth through innovation and return value to shareholders."

The company, through its subsidiary Aphria Deutschland GmbH launched their CBD-based nutraceutical, featuring CBD derived from hemp, CannRelief. The brand of products are being produced in the European Union and distributed by the Company's subsidiary, CC Pharma, which has access to more than 13,000 pharmacies throughout Germany.

"We are excited to introduce our first brand of CBD products for the German nutraceutical and cosmetics market," said Jakob Ripshtein, President of Aphria. "Supported by our extensive distribution network through CC Pharma, CannRelief provides a natural extension to Aphria's growing business opportunities in the German medical cannabis market. We look forward to providing a full range of CannRelief CBD products this year."

CannRelief CBD oils are being sold in both a 5% and 10% CBD concentration and can be found in select stores across Germany. A range of skincare and other products, including creams, serums and masks will be introduced under the CannRelief brand in a phased rollout in 2019.

Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB), a Canadian company that's defining the future of cannabis worldwide, and the UFC, the world's premier mixed martial arts organization, announced their launch of a joint clinical research program that will produce multiple studies under the terms of their recently announced partnership.

The ground-breaking research partnership is aimed at understanding key health and recovery needs of elite athletes in such a highly physical and competitive sport as mixed martial arts. Research data will then be used to drive the development of science-backed, hemp-derived CBD topicals that will be safe and reliable. These new products will help combat the rapidly growing market of untested CBD treatments currently being used by high-performance and non-professional athletes.    

Once research is complete, any resulting product will come to life in the US under the new high-performance sports brand ROAR Sports, a portfolio of high-quality, hemp-derived CBD topical treatments scientifically formulated with elite athletes in mind. Through analysis of athlete needs and scientific data, ROAR Sports will challenge the status quo, seek to alleviate the stresses of competition, and earn designation as the "Official CBD product of UFC."

The multi-phase clinical study at the UFC Performance Institute® in Las Vegas will be led by Dr. Jason Dyck, Chair of Aurora's Global Scientific Oversight Committee; Dr. Kelly Narine, Aurora's Vice President Global Research and Medical Affairs; and the team of sports performance experts at the UFC Performance Institute, led by Dr. Duncan French, UFC Vice President of Performance. Using active UFC athletes on a strictly voluntary basis, the study will help establish peer-reviewed, publishable research in this area. Products will be developed in full compliance with U.S. federal law and with UFC's anti-doping program, which adheres to WADA and USADA regulations.

"Our partnership with UFC is about committing to the science that will educate and advocate," said Aurora CEO, Terry Booth. "We are going to work together to change the way people think, to change the industry, and to launch the first hemp-derived CBD products that are backed by scientific research. The brand-building and product development are all part of our move into the U.S., and in collaboration with UFC, and we intend to play a major role in that market."

"We know anecdotally that professional athletes across sports disciplines are turning to hemp-derived CBD treatments to assist with physical recovery, with varying degrees of success," added Jason Dyck, Chair of Aurora's Global Scientific Oversight Committee. "The work we do in partnership with UFC will create an evidence-based, science-backed pipeline of consistent, and 'clean' hemp-derived CBD topicals that the high-performance athletes of UFC can rely on to treat the pain, inflammation, injury and other conditions associated with competing at such a high level."

"Collaborating with Aurora is the best way to educate ourselves and our fighters about the impact of CBD on MMA athletes and our sport," said Dr. Duncan French, UFC's Vice President of Performance. "We want to apply science and see where it leads us.  Ideally, these studies will give us the clarity we need to determine the effectiveness of hemp-derived CBD on athlete health and injury recovery." 

"Although CBD is allowed under USADA and WADA regulations, we want to be the leaders on educating UFC athletes on CBD use," said Jeff Novitzky, UFC Senior Vice President of Athlete Health & Performance. "Athlete safety is a top priority for UFC, and we will collaborate with Aurora to ensure that any new products are third-party tested for all WADA-prohibited substances to make certain they meet WADA standards."

1933 Industries Inc. (CSE: TGIF) (OTC: TGIFF), a vertically integrated cannabis consumer packaged goods company, recently announced that it will introduce its newest product, the Birdhouse CBD Balm by Canna Hemp X™, on November 4th, 2019. The CBD Balm was developed in collaboration with Birdhouse Skateboards™, targeting the action sports market and will be available for sale in dispensaries, wellness stores, skate shops and specialty retailers, including Zumiez in the United States.

Focusing on the wellness market through the creation of innovative products that enhance and improve people's lives, the Company's CBD-infused line is nationally recognized for its quality and purity of ingredients. Building on its already successful Canna Hemp X™ brand, the new Birdhouse CBD Balm is a must-have for any athlete in need of fast results before, during, and after exercise. The quick-acting Birdhouse CBD Balm is specially formulated with a blend of essential oils, arnica, peppermint, menthol and other natural ingredients. With broad-spectrum CBD, all Canna Hemp™ products are nanoparticulated to ensure total transdermal absorption for maximum effects, while being 100% THC-free.

The sports world is fast embracing the use of cannabidiol or CBD, one of over 100 non-psychoactive and non-addictive compounds extracted from the cannabis plant, in a variety of new products aimed at enhancing performance and recovery. Pro and amateur athletes are now advocating CBD as an alternative to opioid use. "We are just starting to scratch the surface of the many applications associated with the cannabis plant and we are pleased to be part of a national conversation about its potential. The anecdotal benefits keep mounting and we believe that this market is underserved," commented Mr. Chris Rebentisch, 1933 Industries CEO.

He added, "We constantly improve our formulations through research and we worked closely with the Birdhouse team over several months to develop a next-generation CBD topical product that would have wide appeal in the sports world. We are pleased to unveil the Birdhouse CBD Balm that both companies are proud to endorse."

Internationally recognized skateboarding legend Mr. Tony Hawk, Founder of Birdhouse Skateboards™ said, "The Birdhouse CBD Balm is our first collaboration with the team at Canna Hemp X™ and was created with skateboarders and athletes of all levels in mind. Sports like skateboarding require the highest quality recovery products to sustain longevity. We also hope to create awareness of the potential of CBD and in making natural products more accessible nationwide."

As this CBD industry continues to grow, in many ways almost independent of the cannabis sector, brand awareness will become essential as consumers gain more familiarity and awareness of the Hemp/CBD space. As one recent news piece put it, “CBD now has ‘a life of its own’”, and it will be the companies able to build their brands out early through sponsorship agreements, as well as show consistent quality of their innovative formulas that will stand ahead of the rest.

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining,  the AI Eye .

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses of all investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: this news article featuring Real Brands, Inc. RLBD is a paid for news release on Investorideas.com – third party (two thousand) More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Follow us on Social Media

Contact Investorideas.com
800-665-0411



Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories








Trial Could Position Eco-Friendly Fertilizer for Organic Cannabis Market

Trial Could Position Eco-Friendly Fertilizer for Organic Cannabis Market